Printer Friendly

Valeo Pharma and Besins Healthcare Partner for Utrogestan in Canada.

M2 PHARMA-September 18, 2018-Valeo Pharma and Besins Healthcare Partner for Utrogestan in Canada


- Canadian specialty pharmaceutical company Valeo Pharma Inc and pharmaceutical company Besins Healthcare have inked a strategic agreement to commercialise Utrogestan (micronised natural progesterone; 200mg vaginal capsules) in Canada, the companies said.

Utrogestan is indicated for luteal phase support during in-vitro fertilisation cycles.

Under the terms of the agreement with Besins Healthcare, Valeo Pharma is responsible for all aspects of sales, marketing, quality and distribution activities pertaining to Utrogestan 200mg vaginal capsules in Canada.

Valeo Pharma is a specialty pharmaceutical company dedicated to the approval and launch of innovative prescription products in Canada.

With a focus on neurodegenerative diseases, woman's health and rare diseases, Valeo Pharma has a portfolio of innovative products and a platform to properly manage these products through all stages of commercialisation.

Headquartered in Kirkland, Quebec, Valeo Pharma has all capabilities internally to register and market health care solutions for Canadian patients.

Besins Healthcare is a privately owned global pharmaceutical company headquartered in Monaco and operations through over twenty fully-owned affiliated companies around the world, including Ascend Therapeutics LLC.

The company is in novel therapies for gynecology and andrology. Besins Healthcare, pioneer in transdermal gels, has developed several natural hormone-based therapies over the years including bioavailable natural progesterone for pregnant women and bioavailable natural testosterone for testosterone deficiency syndromes.

Utrogestan 100 mg oral is used to reduce the symptoms of menopause (change of life).

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:1CANA
Date:Sep 18, 2018
Previous Article:CBR Touts Positive Results for First Study Administering Cord Blood to Children with Hearing Loss.
Next Article:Janssen submits erdafitinib's NDA with the US FDA for the treatment of metastatic urothelial cancer.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters